ITA1874
ITA1874
ITA1874
from
$526.00
Price in reward points: 526
- Catalog: ITA1874
- Gene/Protein: MAP3K8
- Product Description: Immunotag™ COT Antibody
-
Description
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein COT Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC,IF/ICC,ELISA Recommended Dilution WB 1:500-1:2000 IHC 1:50-1:200 IF/ICC 1:100-1:500 Concentration 1 mg/ml Reactive Species Human,Mouse,Rat Host Species Rabbit Immunogen A synthesized peptide derived from human COT Specificity COT Antibody detects endogenous levels of total COT Purification The antiserum was purified by peptide affinity chromatography. Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt Gene Name MAP3K8 Accession No. P41279 Alternate Names AURA2; c COT; Cancer Osaka thyroid oncogene; CCOT; COT; COT proto oncogene serine/threonine protein kinase; EST; ESTF; Ewing sarcoma transformant; FLJ10486; M3K8_HUMAN; MAP3K 8; MAP3K8; MEKK8; Mitogen activated protein kinase kinase kinase 8; Mitogen-activated protein kinase kinase kinase 8; Proto oncogene cCot; Proto-oncogene c-Cot; Serine/threonine protein kinase cot; Serine/threonine-protein kinase cot; TPL 2; TPL-2; TPL2; Tumor progression locus 2; Description Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant. Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 60kDa Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | COT |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC,IF/ICC,ELISA |
| Recommended Dilution | WB 1:500-1:2000 IHC 1:50-1:200 IF/ICC 1:100-1:500 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse,Rat |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human COT |
| Specificity | COT Antibody detects endogenous levels of total COT |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | MAP3K8 |
| Accession No. | P41279 |
| Alternate Names | AURA2; c COT; Cancer Osaka thyroid oncogene; CCOT; COT; COT proto oncogene serine/threonine protein kinase; EST; ESTF; Ewing sarcoma transformant; FLJ10486; M3K8_HUMAN; MAP3K 8; MAP3K8; MEKK8; Mitogen activated protein kinase kinase kinase 8; Mitogen-activated protein kinase kinase kinase 8; Proto oncogene cCot; Proto-oncogene c-Cot; Serine/threonine protein kinase cot; Serine/threonine-protein kinase cot; TPL 2; TPL-2; TPL2; Tumor progression locus 2; |
| Description | Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 60kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |